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A growing body of evidence demonstrates that persistent positive symptoms, particularly delusions, can be improved by cog-
nitive behaviour therapy for psychosis. Heightened perception and processing of threat are believed to constitute the genesis of
delusions. The present study aimed to examine functional brain changes following cognitive behaviour therapy for psychosis.
The study involved 56 outpatients with one or more persistent positive distressing symptoms of schizophrenia. Twenty-eight
patients receiving cognitive behaviour therapy for psychosis for 6–8 months in addition to their usual treatment were matched
with 28 patients receiving treatment as usual. Patients’ symptoms were assessed by a rater blind to treatment group, and they
underwent functional magnetic resonance imaging during an affect processing task at baseline and end of treatment follow-up.
The two groups were comparable at baseline in terms of clinical and demographic parameters and neural and behavioural
responses to facial and control stimuli. The cognitive behaviour therapy for psychosis with treatment-as-usual group (22 sub-
jects) showed signiﬁcant clinical improvement compared with the treatment-as-usual group (16 subjects), which showed no
change at follow-up. The cognitive behaviour therapy for psychosis with treatment-as-usual group, but not the treatment-
as-usual group, showed decreased activation of the inferior frontal, insula, thalamus, putamen and occipital areas to fearful and
angry expressions at treatment follow-up compared with baseline. Reduction of functional magnetic resonance imaging re-
sponse during angry expressions correlated directly with symptom improvement. This study provides the ﬁrst evidence that
cognitive behaviour therapy for psychosis attenuates brain responses to threatening stimuli and suggests that cognitive behav-
iour therapy for psychosis may mediate symptom reduction by promoting processing of threats in a less distressing way.
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Abbreviations: CBT = cognitive behaviour therapy; PANSS = Positive and Negative Syndrome Scale; TAU = treatment as usual
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According to Beck’s cognitive model of psychopathology (Beck,
1963), biased processing of external and/or internal events or sti-
muli distorts an individual’s construction of experiences and leads
to problematic behavioural and emotional responses. This model
served as the basis for development of cognitive behaviour ther-
apy (CBT) for depression 440 years ago (Beck, 2005). Numerous
studies since then have established the effectiveness of CBT,
applied in varied forms depending upon the cognitive formulation
of a particular disorder, in reducing symptoms across a range of
psychiatric disorders, including obsessive compulsive disorder,
social phobia, panic disorder and psychosis (Butler et al., 2006).
The most common application of CBT for psychosis has been as an
additional treatment to drug therapy for medication-resistant pa-
tients with schizophrenia, with its beneﬁcial effects evident as a
reduction in persistent positive symptoms, particularly delusions,
and secondary disturbances such as depression (Pfammatter
et al., 2006; Wykes et al., 2008; NICE, 2009).
The neuroscience of CBT is a novel area with important impli-
cations for our understanding of the mechanisms of maintenance
of symptoms and of therapeutic change (Brenner et al., 2006; van
der Gaag, 2006). A number of studies have already documented
signiﬁcant neural changes following psychological therapies for
depression (Martin et al., 2001; Goldapple et al., 2004; Fu
et al., 2008), obsessive compulsive disorder (Schwartz et al.,
1996), panic disorder (Prasko et al., 2004) and social (Furmark
et al., 2002) and animal phobias (Paquette et al., 2003; Straube
et al., 2006; Schienle et al., 2009).
The aim of the present study was to examine, for the ﬁrst time
to our knowledge, what kind of functional brain changes, if any,
might emerge following CBT for psychosis in patients with persist-
ent and distressing positive symptom(s) of schizophrenia. To
achieve this, we applied functional MRI during implicit processing
of facial expressions denoting direct as well as indirect threat
(Frijda, 1986; Fridlund, 1994). Angry expressions signal a direct
and immediate threat, while fearful expressions indicate the pres-
ence of a signiﬁcant, but uncertain, source of threat in the envir-
onment (Fridlund, 1994). Paranoia, a main symptom of psychosis,
is fundamentally a threat response (Freeman et al., 2002).
Heightened perception and processing of social threat has been
suggested to constitute the genesis of persecutory delusions
(Green and Phillips, 2004), explained at least in part by inappro-
priate engagement of the brain’s fear system (Corlett et al., 2010).
Both a pre-attentive bias for detection of threat-related informa-
tion as well as difﬁculty disengaging threat-related emotional ma-
terial from conscious awareness are considered to be involved in
delusional beliefs (Green and Phillips, 2004).
Given consistent evidence for improvement in persistent posi-
tive symptoms, especially delusions, after CBT for psychosis
(Pfammatter et al., 2006; Wykes et al., 2008; Rathod et al.,
2010), and the association between paranoia and aberrant pro-
cessing of social threat (Green and Phillips, 2004), the present
investigation tested the hypothesis that psychotic individuals with
persistent positive symptoms of schizophrenia following a course
of CBT for psychosis would display attenuated neural processing
within the network of brain regions processing facial expressions,
particularly those related to threat (i.e. fearful and angry expres-
sions). The network of regions processing emotional facial expres-
sions includes visual (fusiform gyrus, inferior and middle occipital
gyrus, lingual gyrus), limbic (amygdala, parahippocampal gyrus),
temporoparietal (middle–superior temporal gyrus, parietal lobule),
prefrontal and subcortical areas (putamen), insula and the cerebel-
lum (Fusar-Poli et al., 2009). Of these regions, activation of the
amygdala, which signiﬁes fear processing (LeDoux, 2000), and of
the insula, which is associated with anticipation and evaluation of
potentially distressing cognitive and sensory information (Reiman
et al., 1997; Kumari et al., 2009a), was hypothesized in particular
to show reduced activation following a course of CBT for psych-
osis. No speciﬁc hypothesis was formulated with regard to neural
response to happy expressions since enhancement of positive
emotions is not a primary target of CBT for psychosis.
Materials and methods
Participants and design
The investigation involved 56 outpatients, 54 with paranoid schizo-
phrenia and two with schizoaffective disorder diagnosed by a trained
psychiatrist using the Structured Clinical Interview for DSM-IV (SCID;
First et al., 1995). All patients included in this study: (i) were right-
handed; (ii) had no history of neurological conditions or head injury;
(iii) had been on stable doses of antipsychotics for 52 years, and on
the present antipsychotic for 43 months; (iv) received a rating of
560 on the Positive and Negative Syndrome scale (PANSS) (Kay
et al., 1987) and had at least one persistent positive symptom (a
score of 3 or above on at least one of the positive symptoms items
of the PANSS, which they experienced as distressing); and (v) were
willing to receive 6–8 months of CBT for psychosis in addition to their
usual treatment.
Of the 56 patients who participated in this study, 28 patients re-
ceived CBT for psychosis for 6–8 months in addition to their usual
treatment (CBT for psychosis + TAU group) and 28 continued to re-
ceive treatment as usual (TAU-alone group). The patients in the CBT
for psychosis + TAU and TAU-alone groups were recruited from the
same geographical area (South London, UK) and were identiﬁed by
local psychiatric consultants as suitable for CBT for psychosis. The re-
cruitment of patients into the study and the creation of study groups
followed a cohort case-controlled design and involved the following
steps: (i) a patient referred by his/her local consultant and accepted for
CBT for psychosis by the Psychological Interventions Clinic for
Outpatients with Psychosis (PICuP), South London and Maudsley
NHS Foundation Trust; (ii) study introduced to the patient by PICuP
staff; (iii) patient contacted by research team if interested in taking
part in functional MRI study; (iv) if suitable clinically and functional
MRI compatible (e.g. no metal in the body) patient recruited into the
functional MRI study as part of the CBT for psychosis + TAU group;
and (v) another patient with similar demographic and clinical charac-
teristics (to that of the patient included in the CBT for psychosis + TAU
group) recruited for the TAU-alone group via local consultants and
studied over the same interval as the CBT for psychosis + TAU
group. With the resources then available to the South London and
Maudsley NHS Foundation Trust, out of all patients potentially eligible
for CBT for psychosis, only 10% patients were referred for CBT for
psychosis at the time of patient recruitment (March 2003–June 2007).
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osis. Allocation of CBT for psychosis was driven by clinical resource
limitations of the NHS Trust and not by patient characteristics. The
researchers were independent of clinical decisions regarding which
patients were referred for CBT for psychosis.
All patients underwent clinical assessment and functional MRI during
the affect processing task at entry and follow-up (6–8 months later).
TAU-alone patients were followed-up over the same period as CBT for
psychosis + TAU patients in order to conﬁrm CBT for psychosis led,
rather than non-speciﬁc (time effect), symptom improvement and
functional brain changes in the CBT for psychosis + TAU group.
Of 28 patients initially recruited in each group, 22 patients of the
CBT for psychosis + TAU group and 16 patients of the TAU-alone
group completed all assessments at baseline and follow-up and pro-
vided usable data. These patients had remained on the same type and
dosage of antipsychotic medication during the follow-up period.
Consent withdrawal, medication change or non-compliance and in-
complete or unusable imaging data at baseline or follow-up were
the primary reasons for patient drop-outs or exclusion from the study.
Table 1 presents clinical and demographic characteristics of the ﬁnal
sample.
The study was approved by the research ethics committee of the
Institute of Psychiatry and the South London and Maudsley NHS
Foundation Trust (Ref 209/02). All participants provided written informed
consent after the study procedures had been explained to them.
Cognitive behaviour therapy for
psychosis and treatment-as-usual
procedures
After baseline assessments, the CBT for psychosis + TAU group rece-
ived 6–8 months of CBT for psychosis following a published manual
(Fowler et al., 1995) as described in our earlier studies (Kumari et al.,
2009b, 2010). Therapy sessions were conducted weekly or fortnightly,
as preferred by the patient, for up to 1 h. Patients received an average
of 16 sessions, as recommended by NICE guidelines in the UK (NICE,
2009). All CBT for psychosis interventions were formulation driven,
and focused on the therapy goals of the patient. The Psychological
Interventions Clinic for Outpatients with Psychosis (South London and
Maudsley NHS Foundation Trust) has evidence of good therapy out-
comes (Peters et al., 2010). The therapists were supervised by one of
the two investigators (E.K., E.R.P.) who have extensive experience of
CBT for psychosis. The treatment adherence was recorded via fort-
nightly supervision. In addition, a small, random selection of therapy
sessions (n=13) were taped and sent to an independent, experienced
CBT for psychosis therapist to be rated for ﬁdelity of treatment using
the Cognitive Therapy Scale for Psychosis (Haddock et al., 2001). TAU
provided to all patients prior to and during the study consisted of
management offered by a case management team with a dedicated
care coordinator who saw the patient on a regular basis, in addition to
Table 1 Demographics, task performance and clinical characteristics of participants
Demographics CBT for psychosis + TAU group (n=22, 18 males) TAU-alone group (n=16, 14 males)
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Baseline Follow-up Baseline Follow-up
Age (years) 35.68 (7.82) 39.19 (9.37)
Education (years) 13.90 (3.26) 13.56 (1.71)
Predicted IQ
a 109.38 (9.68) 106.64 (9.73)
Age at illness onset (years) 24.77 (8.38) 25.81 (8.49)
Duration of illness (years) 10.91 (7.70) 13.37 (10.16)
Performance
Gender discrimination accuracy (%)
Neutral 92.62 (10.81) 91.76 (13.14) 88.28 (10.79) 90.04 (14.57)
Fear 90.48 (14.35) 91.36 (16.53) 87.89 (20.94) 87.89 (18.46)
Anger 88.63 (15.23) 88.92 (14.16) 84.77 (16.05) 87.30 (19.07)
Happy 94.74 (8.48) 93.32 (9.94) 92.38 (7.82) 90.82 (12.31)
Detection (%)
No face 93.39 (12.39) 91.48 (16.42) 93.80 (13.72) 92.48 (18.12)
PANSS
b symptoms
Positive symptoms 18.09 (4.84) 14.86* (4.10) 18.56 (3.20) 18.06 (3.30)
Negative symptoms 17.73 (4.23) 15.59* (4.29) 19.13 (4.13) 20.31 (4.38)
General psychopathology 33.45 (7.24) 28.59* (7.40) 35.38 (4.41) 35.38 (6.49)
Total symptoms 69.27 (13.30) 59.04* (14.73) 73.06 (9.28) 73.75 (11.83)
Antipsychotic medication
Type 20 patients on atypical;
2 on both atypical and
typical antipsychotics
As baseline 14 patients on atypical;
2 on both atypical and
typical antipsychotics
As baseline
Dose in chlorpromazine
equivalents (mg)
543.00 (479.34) 448.92 (338.84)
Duration of illness = current age minus age of illness onset.
a National Adult Reading Test (Nelson and Willison, 1991).
bK a yet al. (1987).
*Symptom reduction (P50.05) in the CBT for psychosis + TAU, relative to the TAU alone group (no signiﬁcant change in TAU-alone group, P40.05), at follow-up
relative to baseline.
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vocational advisor, as needed.
Symptom assessment
Symptoms were rated in all patients, using the PANSS (Kay et al.,
1987), at entry (baseline) and then 6–8 months later (follow-up) by
an experienced psychiatrist (D.F.), who had no role in clinical manage-
ment and was blind to whether patients received CBT for psychosis
or not. Appointments for these assessments were made by another
member of the research team.
Functional magnetic resonance imaging
paradigm and procedure
Participants were presented with black and white pictures depicting
facial emotions (Ekman and Friesen, 1976). Three types of emotions
(fear, anger, happiness; 100% expression) and relatively neutral ex-
pressions were shown in 30-s blocks of eight pictures each, with each
picture presented for 3.75s. There were 16 30-s blocks with facial ex-
pressions (four fear, four anger, four happy, four neutral), each fol-
lowed by a 15-s control block during which an oval frame, as in facial
expression trials and matched for luminance but without the face
inside, appeared four times. We used this non-face condition, and
not neutral facial expressions, as the control condition because indi-
viduals with schizophrenia (Horley et al., 2001, Hall et al., 2008) and
those at a high risk of psychosis (Seiferth et al., 2008) may respond to
neutral expressions as if they were threatening and are reported to
activate brain regions that are normally associated with fear processing
while viewing neutral expressions (Hall et al., 2008; Seiferth et al.,
2008). The sequence of presentation of fear, anger, happy and neutral
blocks was counterbalanced over the 12-min experiment. On presen-
tation of each facial expression, participants were required to indicate
whether the face was male or female by pressing the left (female) or
the right (male) button on a button box to ensure they were attending
to the stimuli. During the ‘no face’ control condition, attention was
monitored by asking participants to press either button (left or right)
when the blank oval frame appeared. Patients underwent task famil-
iarization in advance of the scan through practice of the gender dis-
crimination task once on all identities used in the functional MRI
experiment on a laptop computer and an identical button box device.
They were requested to abstain from alcohol for at least 24h prior to
their scanning.
Image acquisition
Echoplanar magnetic resonance brain images were acquired using
a 1.5T GE Signa system (General Electric). In each of 16 near-axial
non-contiguous planes parallel to the intercommissural plane, 240
T2*-weighted magnetic resonance images depicting blood oxygen
level-dependent contrast (echo time 40ms, repetition time 3s, ﬂip
angle 90, ﬁeld of view 240mm, matrix 64  64, in-plane resolution
3.1mm, slice thickness 7.0mm, interslice gap 0.7mm) were acquired
over the experiment. In the same session, a high-resolution 3D inver-
sion recovery prepared spoiled gradient recalled acquisition in the
steady state volume data set was acquired with echo time = 5.3ms,
inversion time = 300ms, repetition time = 12.2ms, in-plane reso-
lution = 0.94mm, slice thickness = 1.5mm.
Data analysis
Behavioural measures
The CBT for psychosis + TAU and TAU-alone groups were compared
on age, education, predicted IQ (Nelson and Willison, 1991) and
baseline PANSS symptoms using independent-sample t-tests.
The change in symptoms from baseline to follow-up was investi-
gated using a Group (CBT for psychosis + TAU, TAU alone)  Time
(baseline, follow-up) analysis of variance (ANOVA) with Group as the
between-subjects factor and Time as the within-subjects factor. A sig-
niﬁcant Group  Time effect was followed-up by paired t-tests on
total and subscale PANSS scores separately in the CBT for
psychosis + TAU and TAU-alone groups. Following the observation
of signiﬁcant symptom reduction in the CBT for psychosis + TAU,
but not in the TAU-alone group (refer to the ‘Results’ section), we ex-
amined potential associations between baseline symptom severity and
symptom change (total baseline minus total follow-up) in the CBT for
psychosis + TAU group using Pearson’s correlations, and conﬁrmed
the effects of CBT for psychosis using ANCOVAs on symptom
change scores after co-varying for baseline symptoms. We then calcu-
lated the symptom change data (baseline minus follow-up) on an
item-to-item basis to ﬁnd out which items showed the strongest im-
provement (top six) with CBT for psychosis and, given earlier ﬁndings
of a positive relationship between persecutory delusions and depres-
sion in psychosis (e.g. Freeman et al., 1998; Smith et al., 2006),
explored the interrelationships among these items at baseline across
the whole sample using Spearman correlations.
Performance data (percentage of correct gender discrimination in fa-
cial expressions) were analysed by a Group (CBT for psychosis + TAU,
TAU alone)  Time (baseline, follow-up)  Task (fear, anger, happy,
neutral) ANOVA with Group as a between-subjects factor and Time
and Task as the within-subjects factors, followed by analysis of lower
order effects as appropriate. Performance data in ‘no face’ control
trials (percentage of responses to control stimuli) were similarly ana-
lysed by Group  Time ANOVA.
All analyses were performed using Statistical Package for Social
Sciences (version 16). Alpha level for testing signiﬁcance of effects
was maintained at P50.05.
Functional magnetic resonance imaging
For preprocessing, the 240 volume functional time series of each par-
ticipant was motion corrected, transformed into stereotactic space
(Montreal Neurological Institute, MNI), smoothed with a 8-mm full
width at half maximum Gaussian ﬁlter and band pass ﬁltered using
statistical parametric mapping software (SPM5; http://www.ﬁl.ion.ucl
.ac.uk/spm).
Models and statistical inferences
Data were analysed using a random effect procedure (Friston et al.,
1999). Subject-speciﬁc activations were identiﬁed with a factorial
model consisting of four facial expression conditions, and no face con-
trol condition serving as an implicit baseline. The boxcar for each 30-s
epoch was convolved with the haemodynamic response function.
Motion parameters were included as covariates at this stage. Generic
task-related activations across all patients at baseline were identiﬁed
(height threshold P50.005; cluster corrected P40.05) for each facial
expression condition using one-sample t-tests. The effect of CBT for
psychosis was investigated within a series of Group (CBT for
psychosis + TAU, TAU alone)  Time (baseline, follow-up) ANOVAs
for each of: fearful, angry, happy and neutral expressions versus con-
trol T-image contrasts to identify regions with signiﬁcant Group, Time
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rected P40.05). Both CBT for psychosis + TAU4TAU alone and
TAU alone4CBT for psychosis + TAU sides of the interaction were
examined. We also examined one sample and ANOVA analyses for
individual voxels surviving family-wise error correction at the voxel
level (P50.05) to identify effects in small regions (e.g. the amygdala
or thalamic nuclei), which might be missed using a test of signiﬁcance
based on the extent of activation (i.e. cluster level correction for mul-
tiple comparisons—none found, thus not reported further).
Next, subject-speciﬁc mean blood oxygen level-dependant signal at
baseline and follow-up from each of the clusters that showed a change
at follow-up in the CBT for psychosis group (no cluster showed a
change in the TAU-alone group; see ‘Results’ section) were extracted
using the MarsBaR toolbox (http://marsbar.sourceforge.net/projects/
marsbar). A difference in signal from baseline to follow-up was calcu-
lated for each subject and correlated (Pearson’s r) with change from
baseline to follow-up in (total and subscale) PANSS scores. These add-
itional analyses allowed us to address the question of how brain
changes at follow-up were associated with the change in symptoms.
Such correlations were ﬁrst performed in the CBT for psychosis + TAU-
alone group, and then across the whole sample. Given the lack of
change in symptoms and brain activity from baseline to follow-up in
the TAU-alone group (see ‘Results’ section), there was insufﬁcient
power for this analysis in the TAU-alone group on its own.
Results
Demographic, clinical and behavioural
measures: baseline comparisons
The ﬁnal CBT for psychosis + TAU and TAU-alone groups were
comparable in age, education, predicted IQ, symptoms, age at
illness onset, illness duration and task performance at baseline
(P40.05) (Table 1).
Effects of cognitive behaviour therapy
for psychosis
The CBT for psychosis + TAU, but not the TAU-alone, group
showed changes in symptoms from baseline to follow-up
[Group  Time: total PANSS scores, F(1,36) = 7.23, P = 0.011;
positive symptoms, F(1,36) = 4.45, P = 0.042; negative symptoms,
F(1,36) = 5.84, P = 0.021; general psychopathology: F(1,36) =
4.42, P = 0.043] (Table 1). Only the CBT for psychosis + TAU
group showed reduced symptoms at follow-up [total PANSS
scores: t(21) = 3.72, P = 0.001; positive symptoms: t(21) = 3.90,
P = 0.001; negative symptoms: t(21) = 2.61, P = 0.016; general
psychopathology: t(21) = 2.97, P = 0.007].
Baseline symptoms were not associated with CBT for psychosis
responsiveness (P40.30). Thus, as can be expected, Group ef-
fects in symptom change scores (indicating symptom improvement
in CBT for psychosis + TAU relative to the TAU alone) remained
signiﬁcant after co-varying for baseline symptoms [total PANSS
scores, F(1,35) = 10.17, P = 0.003; positive symptoms, F(1,35) =
7.66, P = 0.009; negative symptoms, F(1,35) = 10.08, P = 0.003;
general psychopathology: F(1,35) = 7.46, P = 0.01].
Of 30 individual PANSS items, the strongest effects of CBT
for psychosis were found on PANSS-P1 (delusions), PANSS-P6
(persecution), PANSS-N2 (emotional withdrawal), PANSS-N4 (pas-
sive social avoidance), PANSS-G6 (depression) and PANNS-G16
(active social avoidance) ratings. Correlational analyses of baseline
symptom ratings across the whole sample revealed that the
patients rated highly on the persecution item (PANSS-P6) were
also rated highly on delusions (PANSS-P1,  = 0.363, P = 0.04)
and active social avoidance (PANNS-G16,  = 0.505, P = 0.001).
Furthermore, those who were rated highly on active social avoid-
ance were rated highly on emotional withdrawal (PANSS-N2,
 = 0.331, P = 0.04), passive social withdrawal ( = 0.329,
P = 0.04) and depression items ( = 0.386, P = 0.020).
Task performance
Patients showed a high level of gender discrimination accuracy
across all conditions (Table 1); this was expected given the easy
task demands, implemented simply to ensure patients’ attention
to task stimuli and not place cognitive demands on them. The CBT
for psychosis + TAU and TAU-alone groups displayed similar per-
formance during all conditions on both occasions (F51 for
Group, Group  Time, Group  Task and Group  Time  Task
effects).
Baseline functional magnetic resonance
imaging patterns
The areas showing increases during individual facial expressions
across all patients at baseline are described in Table 2. The com-
parison relates to the control blank oval stimuli and thus will also
reveal activity related to low-level visual aspects of the face stimuli
such as spatial variations in contrast. The activated regions at
baseline identiﬁed across all patients for fearful expressions, rela-
tive to the control condition, included the inferior frontal gyrus,
insula, thalamus, amygdala, parahippocampal gyrus, putamen
(all right sided) and cerebellum (left) along with robust bilateral
activation in the inferior–middle occipital and fusiform gyri. The
activated regions identiﬁed for angry expressions included the in-
ferior frontal gyrus (bilateral), thalamus (bilateral), anterior insula
(right), amygdala (right), putamen (bilateral), cerebellum (right)
and robust bilateral activation of the inferior–middle occipital
and fusiform gyri. Many of these areas were also activated for
neutral expressions. Happy expressions robustly activated only
the right visual areas. CBT for psychosis + TAU and TAU-alone
groups did not differ signiﬁcantly in baseline activation of these
areas.
Functional magnetic resonance imaging changes
following cognitive behaviour therapy for psychosis
in addition to usual treatment versus usual
treatment alone
Group  Time effects at a stringent threshold of signiﬁcance
(P50.05 cluster corrected) were found in the bilateral inferior
frontal gyrus, right insula, bilateral putamen, left thalamus and
left occipital areas during the processing of fearful expressions
(Table 3). The CBT for psychosis + TAU group showed a greater
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(Fig. 1A), compared with the activity decrease at follow-up (rela-
tive to baseline) in the TAU-alone group (i.e. difference of the
differences). No Group  Time effects were found at the same
level of signiﬁcance during the processing of angry expressions.
However, at a lower threshold (P50.05 uncorrected cluster), ef-
fects were found in the left inferior frontal gyrus, left anterior
insula, bilateral putamen and left occipital areas during the pro-
cessing of angry expressions (Table 3). These indicated a greater
activity decrease in the CBT for psychosis + TAU group in these
areas at follow-up (relative to baseline), compared with the activ-
ity decrease at follow-up (relative to baseline) in the TAU-alone
group (Fig. 1D).
We did not ﬁnd any regions in which the TAU-alone group
showed signiﬁcantly greater activity increases or decreases from
baseline to follow-up than the CBT for psychosis + TAU group.
Group  Time effects were not found at a corrected or uncor-
rected cluster level of signiﬁcance for happy or neutral expressions.
Also, no area showed a signiﬁcant Time [i.e. change from baseline
to follow–up (6–8 months later) across both groups] or a Group
Table 2 Activation increases to individual facial expressions compared with non-face control stimuli across all patients at
baseline (voxel threshold P50.005 uncorrected)
Brain area Brodmann
area
Voxels (n) Side MNI Coordinates Voxel T Cluster-
corrected,
P-value xyz
Fearful
Inferior–middle occipital gyrus 19 2196 Right 38  80 8 10.61 50.001
19 Right 44 68 14 8.63
Fusiform gyrus 37 Right 38 46 24 8.59
Fusiform gyrus 37 993 Left 38 64 20 8.23 50.001
Culmen Left 38 48 26 7.25
Middle occipital gyrus 18 Right 20 92 0 5.87
Parahippocampal gyrus 27 1274 Right 20 32 4 5.11 0.001
Insula—extends to inferior frontal gyrus,
amygdala and putamen
Right 42 10 10 4.25
Right 34 8 8 3.82
Angry
Inferior occipital gyrus 18/19 3175 Right 42 72 8 10.24 50.001
Culmen Right 38 50 26 9.64
Middle occipital gyrus 18 Right 28 92 0 9.38
Fusiform gyrus 37 922 Left 42 64 20 8.47 0.009
Culmen Left 36 48 26 6.43
Middle occipital gyrus 19 Left 38 68 10 6.04
Amygdala 3637 Right 20 2 18 5.91 50.001
Thalamus—extends to putamen Right 14 32 2 5.75
Left 12 22 0 5.64
Inferior frontal gyrus 44 873 Left 46 16 22 5.47 0.011
45 Left 46 30 8 4.35
47 Left 48 40 0 3.25
Inferior frontal gyrus—extends to
part of anterior insula
44 1369 Right 46 8 44 4.65 0.001
45 Right 50 32 12 4.62
44 Right 42 8 32 4.05
Neutral
Middle–inferior occipital gyrus 18 2059 Right 28 92 0 8.84 50.001
19 Right 42 70 12 8.61
18 Right 34 84 8 7.30
Fusiform gyrus 37 1009 Left 42 64 20 7.77 0.012
Inferior occipital gyrus 19 Left 38 74 8 6.23
Culmen Left 36 48 26 6.08
Parahippocampal gyrus 27 4685 Right 18 32 4 6.65 50.001
Transverse temporal gyrus 41 Left 48 22 12 4.50
Post-central gyrus 6 Left 46 10 2 4.39
Putamen 1062 Right 30 4 2 5.02 0.01
Insula Right 44 0 12 3.59
Thalamus Right 22 12 18 3.18
Happy
Middle–inferior occipital gyrus 18 1823 Right 28 92 0 8.23 50.001
18 Right 40 74 12 6.71
18/19 Right 34 84 8 5.96
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any facial expressions.
Relationship between functional magnetic resonance
imaging changes and symptom improvement
For each region showing a signiﬁcant (fearful expressions—cor-
rected cluster threshold) or nominally signiﬁcant (angry expres-
sions—uncorrected cluster threshold) Group  Time effect, we
extracted parameter estimates for each subject and explored
their relationship with change in PANSS total and subscale
scores. For fearful expressions, no region correlated with any of
the PANSS change scores (Table 4). In contrast, for angry expres-
sions, reduction in all regions correlated positively with symptom
improvement (Table 5). These relationships were generally weaker
for negative symptoms, possibly because this symptom dimension
also showed the least change (of all PANSS dimensions) following
CBT for psychosis (Table 1).
Discussion
This study investigated neural changes following 6–8 months of
CBT for psychosis in patients with schizophrenia using functional
MRI and an implicit affective processing task.
Clinical and behavioural ﬁndings
The ﬁnal CBT for psychosis + TAU and TAU-alone groups, after
loss of some patients from the study, were matched with no evi-
dence of differences between the two groups in demographic or
clinical characteristics. The two patient groups were also equally
attentive to the simple task requirements, as shown by their per-
formance level, both at baseline and follow-up.
As expected, based on the ﬁndings of meta-analyses of rando-
mized controlled trials of CBT for psychosis (Pfammatter et al.,
2006; Wykes et al., 2008; NICE, 2009), the CBT for
psychosis + TAU group, on average showed signiﬁcantly reduced
symptom severity at follow-up, relative to the TAU-alone group.
The clinical improvement following CBT for psychosis in the pre-
sent study was of similar magnitude to that observed by several
randomized controlled trials (Butler et al., 2006; Pfammatter et al.,
2006; Wykes et al., 2008) and conﬁrms that well-designed studies
with a cohort- or case-control design do not systematically over-
estimate treatment effects (Concato et al., 2000). Of 30 PANSS
items, the effect of CBT for psychosis were most pronounced on
persecution, delusions (positive symptoms), emotional withdrawal,
passive social withdrawal (negative symptoms), and depression
and active social avoidance (general psychopathology). In line
with earlier ﬁndings of a positive relationship between persecutory
delusions and depression in psychosis (Freeman et al., 1998; Smith
et al., 2006), baseline ratings on these individual symptoms across
Table 3 Signiﬁcant decreases after CBT for psychosis + TAU, compared with TAU alone (no signiﬁcant change), during
fearful and angry facial expressions (voxel threshold P50.005 uncorrected)
Brain area Brodmann
area
Voxels (n) Side MNI Coordinates Voxel T Cluster,
P-value
xy z
Fearful
Inferior frontal gyrus 45 1567 Left 50 20 10 4.74 50.001
45 Left 44 30 8 4.35
45 Left 52 12 2 4.02
Inferior frontal gyrus 45 2863 Right 40 22 4 4.54 50.001
45 Right 60 14 6 4.24
Precentral gyrus 6 Right 50 0 10 4.08
Putamen (lentiform nucleus) Right 28 2 10 4.06
Insula 13 Right 42 14 4 3.29
Lingual gyrus 19 1047 Left 24 74 8 3.95 0.003
19 Left 8 76 2 3.78
19 Left 6 66 2 3.66
Putamen (lentiform nucleus) 559 Left 26 0 6 3.80 0.05
Claustrum Left 32 14 10 3.66
Thalamus Left 12 8 8 3.01
Angry
Inferior frontal gyrus—extends
to anterior insula
47 255 Left 42 42 0 3.73 0.048
45 Left 32 34 4 3.45
45 Left 44 24 4 3.07
Caudate 248 Left 18 12 20 3.95 0.05
Putamen (lentiform nucleus) Left 18 12 12 2.91
Putamen (lentiform nucleus) 349 Right 26 12 10 3.74 0.024
Cuneus/lingual gyrus 17/18 305 Left 4 78 12 4.10 0.033
Middle occipital gyrus 19 Left 20 88 14 3.43
Cuneus 18 Left 16 72 12 3.35
P-values for Fearful are cluster-corrected, whilst those for Angry are cluster-uncorrected.
2402 | Brain 2011: 134; 2396–2407 V. Kumari et al.Figure 1 (A and D) Areas of reduced brain activity following CBT for psychosis + TAU (CBTp) (but not following TAU alone) to fearful
and angry facial expressions (voxel threshold P50.005 uncorrected) in axial views with associated MNI z co-ordinates. Left hemisphere is
shown on the left. (B) Mean functional MRI response in the left inferior frontal–insula cluster in each group at baseline and follow-up to
fearful expressions. (C) Mean functional MRI response in the left inferior frontal cluster in each group at baseline and follow-up to angry
expressions. (E) Scatter plot of decreases in activity from baseline to follow-up in the left inferior frontal region during angry expressions
against the change in symptoms from baseline to follow-up across the whole sample.
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2404 | Brain 2011: 134; 2396–2407 V. Kumari et al.the whole sample were correlated positively with each other. The
effect of CBT for psychosis on negative (emotional withdrawal,
passive social withdrawal) and general psychopathology (depres-
sion, active social avoidance) symptom dimensions is thus likely to
be related to its effect on positive symptoms (persecution and
delusions), as suggested previously by Kuipers and colleagues
(2006), and to share common neural correlates (our functional
MRI ﬁndings). The meta-analysis by Wykes et al. (2008) not
only conﬁrmed beneﬁcial effects of CBT for psychosis on positive
symptoms, negative symptoms, functioning, mood and social anx-
iety (effect sizes ranging from 0.35 to 0.44) but also found that
improvements in one domain correlated with improvements in
others.
Our TAU-alone group, although limited by a smaller sample size
(n=16), showed no change in symptoms from baseline to follow-
up. This was expected given that our inclusion criteria required all
patients to have stable (although distressing) symptom(s), to be on
the same medication for a minimum of three months prior to
study entry, and no change in their medication during the
course of this investigation.
Baseline functional magnetic resonance imaging
patterns
There were no signiﬁcant differences at baseline between the CBT
for psychosis + TAU and TAU-alone groups in brain response to
emotive and neutral facial expressions. The activations observed
across all patients at baseline, i.e. activation of the amygdala, in-
sula, thalamus, putamen, inferior frontal gyrus, parahippocampal
gyrus and cerebellum, along with robust activation of fusiform
gyrus, are consistent with results of previous studies using facial
stimuli (Phillips et al., 2003; Phan et al., 2004; Britton et al., 2006;
Gur et al., 2007; Fusar-Poli et al., 2009). As conﬁrmed by a recent
meta-analysis (Fusar-Poli et al., 2009), the processing of facial
emotions reliably produces increased activation in a number of
brain areas including the visual (fusiform gyrus, inferior and middle
occipital gyrus, lingual gyrus), limbic (amygdala, parahippocampal
gyrus), temporoparietal (middle–superior temporal gyrus, parietal
lobule), prefrontal and subcortical areas (putamen), insula and the
cerebellum. Although the exact functional interplay among these
regions remains to be established, the occipital and temporal areas
are thought to contribute primarily to early perceptual processing
of faces, with the remaining areas acting to associate perceptual
representation of the face to the generation of the knowledge
about the displayed emotion in the face (Adolphs, 2002).
Functional magnetic resonance imaging changes
following cognitive behaviour therapy for psychosis
with usual treatment versus usual treatment alone
Conﬁrming our hypothesis, CBT for psychosis + TAU group at
follow-up compared with baseline showed attenuation of func-
tional MRI response to fearful and angry expressions. This re-
sponse attenuation was present in the inferior frontal gyrus,
(anterior) insula, putamen, thalamus and visual areas. The inferior
frontal gyrus is an established part of the brain system that pro-
cesses facial expressions (Haxby et al., 2002) and is found to be
more active during explicit, relative to implicit, processing of facial
emotions (Scheuerecker et al., 2007). The insula integrates internal
and external information (Mesulam and Mufson, 1982) and is
believed to play a role in processing of potentially distressing in-
formation (Reiman et al., 1997). Increased insula activation also
occurs when participants attempt to suppress their emotions, with
an opposite effect for reappraisal (Goldin et al., 2008). Delusional
information processing has been suggested to involve an initial
vigilance for threat, followed by active avoidance of threat
during later controlled information processing stages (Green and
Phillips, 2004). It is plausible that this active avoidance includes
suppression of response to threat. Activation of the inferior front-
al–anterior insula area is also observed during high anticipatory
fear in both healthy and schizophrenia groups (Kumari et al.,
2009a), and this activation is attenuated after the administration
of anxiolytic drug lorazapam in healthy subjects (Schunck et al.,
2010). Recent studies demonstrate basal ganglia response to stress
(Scott et al., 2006). The thalamus, with projections to the amyg-
dala, modulates arousal (Van der Werf et al., 2002; Li and
Kirouac, 2008) and is involved in processing of threat in facial
expressions (Luo et al., 2007). The areas of reduced activation
after 6–8 months of CBT for psychosis in this study included
visual (occipital) areas, which are suggested to be recruited pri-
marily for early perceptual processing (Adolphs, 2002) and receive
feedback from areas processing visual emotion (Catani et al.,
2003). It is possible that CBT for psychosis achieves some of its
clinical beneﬁt by acting on psychological processes involved in
early perceptual processing through feed-back from higher areas
as well as by modulating conscious and explicit processing of
threat-related emotional materials in the inferior frontal gyrus
and other regions.
Contrary to our hypothesis, we did not observe a signiﬁcant
change in amygdala activation following a course of CBT for
psychosis. The reason for this is unclear. It is plausible that CBT
for psychosis in paranoid schizophrenia patients has a relatively
weaker effect on brain regions involved implicitly in generating
emotional responses to simple and perceptual associative aspects
of stimuli (Izard, 1993). This, however, needs to be conﬁrmed
using event-related paradigms and speciﬁc image acquisition and
analytical techniques that allow the temporal course of activation
to be quantiﬁed given that activation of the amygdala may show a
rapid attenuation (Buchel et al., 1998) and functional activity
within this structure is more difﬁcult to image than within other
cortical structures.
Relationship between functional magnetic resonance
imaging changes and symptom improvement
Attenuation of functional MRI activity at follow-up relative to
baseline during angry expressions was correlated directly with a
reduction in symptoms following CBT for psychosis. This may ex-
plain why the Group  Time effects were less signiﬁcant for this
expression as the size of the attenuation varied for different par-
ticipants. We did not show direct correlations with immediate re-
ductions in PANSS symptoms and brain changes with exposure to
fearful faces. It is plausible that some PANSS symptom items are
more relevant to signals of direct threat (angry faces with direct
eye contact) than signals of danger with uncertain source (fearful
faces). Therapists may also have a better deﬁned symptom target
when aiming for a reduction in distress in response to signals of
Functional MRI of cognitive therapy for psychosis Brain 2011: 134; 2396–2407 | 2405potential direct threat (e.g. eye contact from strangers) than sig-
nals of indirect threat. Furthermore, PANSS fails to capture sub-
jective qualities of symptoms and thus is not ideal for measuring
the range of clinical effects of CBT for psychosis (Birchwood and
Trower, 2006). The effect of CBT for psychosis on threat process-
ing observed in this study may also relate to the continued im-
provements that can be seen at a longer follow-up (i.e. 9 months
after the end of CBT for psychosis) (Sensky et al., 2000).
Study limitations
The study was not designed to test the efﬁcacy of CBT for psych-
osis but to observe changes in brain activity over the course of
CBT for psychosis. As such we did not attempt to randomize pa-
tients into different treatment arms but used a cohort
case-controlled design to compare brain activity in patients ac-
cepted for CBT for psychosis by the clinical service with those
continuing to receive standard treatment. It is possible there
were differences in the type of patient accepted for CBT for
psychosis compared with those remaining on standard treatment;
however, such differences are not apparent in any of the clinical or
demographic measures included in the study. Importantly, brain
response at baseline was equivalent in the two groups making it
unlikely the Group  Time effects described could be attributed to
biases introduced by our recruitment method. Another limitation is
that we did not include a measure of anxiety. Anxiety is known to
play a key role in threat perception and paranoia (Green and
Phillips, 2004; Freeman, 2007) and may have been directly asso-
ciated with symptomatic improvement and attenuation of func-
tional MRI activity at follow-up relative to baseline during
exposure to threatening facial expressions. However, PANSS anx-
iety item (PANSS-G2) was not one of the items showing the
strongest effects of CBT for psychosis suggesting that the neural
effects of CBT for psychosis found in this study are unlikely to be
explained simply by a general reduction in anxiety.
Conclusion
This study provides the ﬁrst evidence that a course of 6–8 months
of NICE guideline compliant CBT for psychosis attenuates brain
responses to threatening socially relevant stimuli in people with
psychosis. The demonstration of CBT for psychosis-induced
changes in social cognition at the neural level is an important
development in the ﬁeld. Further studies are required to examine
neural changes accompanying CBT for psychosis-led improvement
on speciﬁc symptoms of schizophrenia, using multidimensional
measures of behavioural change and sophisticated experimental
paradigms with multimodal imaging sensitive to temporal aspects
of brain changes, allowing the effects to be quantiﬁed precisely
during the early processing of threat detection, as well as con-
scious processing of threatening materials.
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